{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:14:11Z","timestamp":1789445651217,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04413-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:34:42Z","timestamp":1759156482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-dose vs. standard-dose alteplase for acute ischemic stroke: a retrospective cohort study of safety and efficacy in an Iranian population"],"prefix":"10.1186","volume":"25","author":[{"given":"Fatemeh","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Zarvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Fayedeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Sharifi-Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"4413_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0028-3886.336328","volume":"70","author":"A Sharifi-Razavi","year":"2022","unstructured":"Sharifi-Razavi A, Karimi N, Jafarpour H. Evaluation of selenium supplementation in acute ischemic stroke outcome: an outcome assessor blind, randomized, Placebo-controlled, feasibility study. Neurol India. 2022;70:87\u201393.","journal-title":"Neurol India"},{"issue":"20Supplement2","key":"4413_CR2","first-page":"S6","volume":"97","author":"V Saini","year":"2021","unstructured":"Saini V, Guada L, Yavagal DR. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 2021;97(20Supplement2):S6\u201316.","journal-title":"Neurology"},{"issue":"12","key":"4413_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.amjmed.2021.07.027","volume":"134","author":"SK Feske","year":"2021","unstructured":"Feske SK. Ischemic stroke. Am J Med. 2021;134(12):1457\u201364.","journal-title":"Am J Med"},{"issue":"1","key":"4413_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/CIRCULATIONAHA.105.593418","volume":"114","author":"I Kronzon","year":"2006","unstructured":"Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation. 2006;114(1):63\u201375.","journal-title":"Circulation"},{"issue":"8","key":"4413_CR5","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cells9081794","volume":"9","author":"S-W Kim","year":"2020","unstructured":"Kim S-W, Lee J-K. Role of HMGB1 in the interplay between NETosis and thrombosis in ischemic stroke: a review. Cells. 2020;9(8):1794.","journal-title":"Cells"},{"key":"4413_CR6","doi-asserted-by":"publisher","unstructured":"Micieli G, Marcheselli S, Tosi PA. Safety and efficacy of Alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009;5(1):397\u2013409.https:\/\/doi.org\/10.2147\/vhrm.s4561","DOI":"10.2147\/vhrm.s4561"},{"key":"4413_CR7","doi-asserted-by":"publisher","first-page":"763963","DOI":"10.3389\/fneur.2022.763963","volume":"13","author":"C-H Chen","year":"2022","unstructured":"Chen C-H, Tang S-C, Chen Y-W, Chen C-H, Tsai L-K, Sung S-F, et al. Effectiveness of standard-dose vs. low-dose Alteplase for acute ischemic stroke within 3\u20134.5\u00a0h. Front Neurol. 2022;13:763963.","journal-title":"Front Neurol"},{"key":"4413_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35571","author":"J Karedath","year":"2023","unstructured":"Karedath J, Avanteeka F, Aslam MN, Nadeem A, Yousaf RA, Shah S, et al. Comparison of effectiveness and safety of low-dose versus standard-dose intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke: a meta-analysis. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.35571.","journal-title":"Cureus"},{"issue":"11","key":"4413_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/CCM.0000000000004597","volume":"48","author":"F Herpich","year":"2020","unstructured":"Herpich F, Rincon F. Management of acute ischemic stroke. Crit Care Med. 2020;48(11):1654\u201363.","journal-title":"Crit Care Med"},{"issue":"2","key":"4413_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.014","volume":"27","author":"J-W Cheng","year":"2018","unstructured":"Cheng J-W, Zhang X-J, Cheng L-S, Li G-Y, Zhang L-J, Ji K-X, et al. Low-dose tissue plasminogen activator in acute ischemic stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2018;27(2):381\u201390.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9","key":"4413_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105073","volume":"29","author":"N Keric","year":"2020","unstructured":"Keric N, D\u00f6bel M, Krenzlin H, Kurz E, Tanyildizi Y, Heimann A, et al. Comparative analysis of fibrinolytic properties of alteplase, tenecteplase and urokinase in an in vitro clot model of intracerebral haemorrhage. J Stroke Cerebrovasc Dis. 2020;29(9):105073.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"4413_CR12","doi-asserted-by":"publisher","first-page":"1165237","DOI":"10.3389\/fneur.2023.1165237","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Ji K, Fang Q. Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset. Front Neurol. 2023;14:1165237.","journal-title":"Front Neurol"},{"issue":"8","key":"4413_CR13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jama.2023.0550","volume":"329","author":"H-S Chen","year":"2023","unstructured":"Chen H-S, Cui Y, Zhou Z-H, Dai Y-J, Li G-H, Peng Z-L, et al. Effect of argatroban plus intravenous alteplase vs intravenous alteplase alone on neurologic function in patients with acute ischemic stroke: the ARAIS randomized clinical trial. JAMA. 2023;329(8):640\u201350.","journal-title":"JAMA"},{"issue":"24","key":"4413_CR14","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","volume":"374","author":"CS Anderson","year":"2016","unstructured":"Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee T-H, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"20","key":"4413_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206641","volume":"12","author":"I Migdady","year":"2023","unstructured":"Migdady I, Johnson-Black PH, Leslie-Mazwi T, Malhotra R. Current and emerging endovascular and neurocritical care management strategies in large-core ischemic stroke. J Clin Med. 2023;12(20):6641.","journal-title":"J Clin Med"},{"issue":"9","key":"4413_CR16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1161\/STROKEAHA.115.010180","volume":"46","author":"BJ Kim","year":"2015","unstructured":"Kim BJ, Han M-K, Park TH, Park S-S, Lee KB, Lee B-C, et al. Low-versus standard-dose Alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study. Stroke. 2015;46(9):2541\u20138.","journal-title":"Stroke"},{"key":"4413_CR17","doi-asserted-by":"publisher","first-page":"884267","DOI":"10.3389\/fneur.2022.884267","volume":"13","author":"B-H Li","year":"2022","unstructured":"Li B-H, Wang J-H, Wang H, Wang D-Z, Yang S, Guo F-Q, et al. Different doses of intravenous tissue-type plasminogen activator for acute ischemic stroke: a network meta-analysis. Front Neurol. 2022;13:884267.","journal-title":"Front Neurol"},{"issue":"7","key":"4413_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1747493019858777","volume":"14","author":"X Wang","year":"2019","unstructured":"Wang X, Li J, Moullaali TJ, Lee K-J, Kim BJ, Bae H-J, et al. Low-dose versus standard-dose Alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study. Int J Stroke. 2019;14(7):670\u20137.","journal-title":"Int J Stroke"},{"issue":"11","key":"4413_CR19","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1161\/STROKEAHA.115.010721","volume":"46","author":"J-P Desilles","year":"2015","unstructured":"Desilles J-P, Loyau S, Syvannarath V, Gonzalez-Valcarcel J, Cantier M, Louedec L, et al. Alteplase reduces downstream microvascular thrombosis and improves the benefit of large artery recanalization in stroke. Stroke. 2015;46(11):3241\u20138.","journal-title":"Stroke"},{"key":"4413_CR20","doi-asserted-by":"publisher","first-page":"1079205","DOI":"10.3389\/fneur.2023.1079205","volume":"14","author":"J Sun","year":"2023","unstructured":"Sun J, Lam C, Christie L, Blair C, Li X, Werdiger F, et al. Risk factors of hemorrhagic transformation in acute ischaemic stroke: a systematic review and meta-analysis. Front Neurol. 2023;14:1079205.","journal-title":"Front Neurol"},{"issue":"4","key":"4413_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jamaneurol.2018.4410","volume":"76","author":"S Song","year":"2019","unstructured":"Song S, Liang L, Fonarow GC, Smith EE, Bhatt DL, Matsouaka RA, et al. Comparison of clinical care and in-hospital outcomes of Asian American and white patients with acute ischemic stroke. JAMA Neurol. 2019;76(4):430\u20139.","journal-title":"JAMA Neurol"},{"key":"4413_CR22","doi-asserted-by":"crossref","unstructured":"Roesly H, Wang X, Robinson T, Lee T et al.\u00a0Low Dose vs. Standard-Dose Alteplase for Patients With Acute Ischemic Stroke. JAMA Neurol 2017;74(11):1328\u20131335. Journal of Emergency Medicine. 2018;54(5):739\u221240.","DOI":"10.1016\/j.jemermed.2018.03.008"},{"key":"4413_CR23","doi-asserted-by":"publisher","unstructured":"Chen C-H, Lee C-W, Hsieh Y-C, Lin C-J, Chen Y-W, Lin K-H et al. Comparing Low-or Standard-Dose Alteplase in endovascular thrombectomy: insights from a nationwide registry. Stroke. 2024;55(3):532\u2013540. https:\/\/doi.org\/10.1161\/STROKEAHA.123.045851","DOI":"10.1161\/STROKEAHA.123.045851"},{"issue":"11","key":"4413_CR24","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1212\/WNL.0000000000011598","volume":"96","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Delcourt C, Xia C, Yoshimura S, Carcel C, Torii-Yoshimura T, et al. Low-dose vs standard-dose Alteplase in acute lacunar ischemic stroke: the ENCHANTED trial. Neurology. 2021;96(11):e1512\u201326.","journal-title":"Neurology"},{"issue":"4","key":"4413_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/STROKEAHA.120.031869","volume":"52","author":"B Jia","year":"2021","unstructured":"Jia B, Ren Z, Mokin M, Burgin WS, Bauer CT, Fiehler J, et al. Current status of endovascular treatment for acute large vessel occlusion in China: a real-world nationwide registry. Stroke. 2021;52(4):1203\u201312.","journal-title":"Stroke"},{"key":"4413_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2018.01.014","volume":"387","author":"G Chen","year":"2018","unstructured":"Chen G, Wang X, Robinson TG, Pikkemaat M, Lindley RI, Zhou S, et al. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and\/or diabetes mellitus: the ENCHANTED trial. J Neurol Sci. 2018;387:1\u20135.","journal-title":"J Neurol Sci"},{"issue":"4","key":"4413_CR27","first-page":"208","volume":"20","author":"E Sadeghi-Hokmabadi","year":"2021","unstructured":"Sadeghi-Hokmabadi E, Ghoreishi A, Rikhtegar R, Sariaslani P, Rafie S, Vakilian A, et al. Low-dose versus standard-dose alteplase for intravenous thrombolysis in patients with acute ischemic stroke in Iran: results from the safe implementation of treatments in stroke registry. Curr J Neurol. 2021;20(4):208\u201313.","journal-title":"Curr J Neurol"},{"issue":"5","key":"4413_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/JNN.0000000000000457","volume":"51","author":"J Staszewski","year":"2019","unstructured":"Staszewski J, D\u0119biec A, Derbich M, Antoniak M, St\u0119pie\u0144 A. Frequency, risk factors, and clinical significance of incorrect dose of Alteplase due to weight estimation in acute ischemic stroke patients: a single-center retrospective study. J Neurosci Nurs. 2019;51(5):267\u201372.","journal-title":"J Neurosci Nurs"},{"key":"4413_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jocn.2020.12.024","volume":"85","author":"C-Y Cheng","year":"2021","unstructured":"Cheng C-Y, Chen S-H, Chen H-M, Li C-J, Liu T-Y, Tan T-Y. Impact of estimated-weight-base dose of Alteplase in acute stroke treatment on clinical outcome. J Clin Neurosci. 2021;85:101\u20135.","journal-title":"J Clin Neurosci"},{"key":"4413_CR30","doi-asserted-by":"publisher","unstructured":"Ro M, Taylor MA, Jones R. Alteplase-and Tenecteplase-Related errors and risk mitigation strategies in the treatment of acute ischemic stroke: A study of event reports from 52 hospitals. Patient Saf (2689\u2009\u2013\u20090143). 2024;6(1):1-19. https:\/\/doi.org\/10.33940\/001c.117322.","DOI":"10.33940\/001c.117322"},{"issue":"2","key":"4413_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.17712\/nsj.2021.2.20200148","volume":"26","author":"GM Salem","year":"2021","unstructured":"Salem GM, El-Sheik WM, El-Shanawany BG, Afifi KH. Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients. Neurosciences (Riyadh). 2021;26(2):179\u201385.","journal-title":"Neurosciences (Riyadh)"},{"issue":"5","key":"4413_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/01616412.2019.1580454","volume":"41","author":"M Liu","year":"2019","unstructured":"Liu M, Pan Y, Zhou L, Wang Y. Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage. Neurol Res. 2019;41(5):473\u20139.","journal-title":"Neurol Res"},{"issue":"7","key":"4413_CR33","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/01.STR.0000227191.01792.e3","volume":"37","author":"T Yamaguchi","year":"2006","unstructured":"Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6\u00a0mg\/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke. 2006;37(7):1810\u20135.","journal-title":"Stroke"},{"issue":"8","key":"4413_CR34","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1161\/STROKEAHA.114.005245","volume":"45","author":"A-C Chao","year":"2014","unstructured":"Chao A-C, Liu C-K, Chen C-H, Lin H-J, Liu C-H, Jeng J-S, et al. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. Stroke. 2014;45(8):2359\u201365.","journal-title":"Stroke"},{"issue":"8","key":"4413_CR35","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/STROKEAHA.114.005989","volume":"45","author":"X Liao","year":"2014","unstructured":"Liao X, Wang Y, Pan Y, Wang C, Zhao X, Wang DZ, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke. 2014;45(8):2354\u20138.","journal-title":"Stroke"},{"issue":"15","key":"4413_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMc1801548","volume":"378","author":"CS Anderson","year":"2018","unstructured":"Anderson CS, Woodward M, Chalmers J. More on low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2018;378(15):1465\u20136.","journal-title":"N Engl J Med"},{"issue":"11","key":"4413_CR37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1001\/jamaneurol.2017.2286","volume":"74","author":"X Wang","year":"2017","unstructured":"Wang X, Robinson TG, Lee T-H, Li Q, Arima H, Bath PM, et al. Low-dose vs standard-dose Alteplase for patients with acute ischemic stroke: secondary analysis of the ENCHANTED randomized clinical trial. JAMA Neurol. 2017;74(11):1328\u201335.","journal-title":"JAMA Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04413-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:34:48Z","timestamp":1759156488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04413-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4413"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04413-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6744684\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Mazandaran University of Medical Sciences (Ethics approval code: IR.MAZUMS.REC.1403.20179). Written informed consent was obtained from all participants or their legal guardians prior to enrollment. The study adhered to the Declaration of Helsinki (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}